<Research>M Stanley Rates FOSUN PHARMA as Overweight With TP HKD32, Lifts Rev. Forecast

News Sharing

For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields

Receiver*

Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com

Your email address*

Content Sharing

<Research>M Stanley Rates FOSUN PHARMA as Overweight With TP HKD32, Lifts Rev. Forecast

Morgan Stanley issued a research report raising FOSUN PHARMA (02196.HK)'s revenue forecasts for 2026-28 by 3%, citing higher sales of innovative drugs and expected recurring li...

Reset

Send

The window will close in 5 seconds

<Research>M Stanley Rates FOSUN PHARMA as Overweight With TP HKD32, Lifts Rev. Forecast

Recommend

Positive

Negative

SHORT SELL

STOCK INFO

aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

Morgan Stanley issued a research report raising FOSUN PHARMA (02196.HK) 0.000 (0.000%) Short selling $11.09M; Ratio 24.891% 's revenue forecasts for 2026-28 by 3%, citing higher sales of innovative drugs and expected recurring licensing income of around RMB800 million per year.

Expecting FOSUN PHARMA to achieve the net profit targets under its employee stock ownership plan for 2026-27, Morgan Stanley rated FOSUN PHARMA as Overweight, alongside a target price of HKD32.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-02 16:25.)

Auto-translated by AI

View Original Text

This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News

Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.